Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THOR-213
- Development stage
- Unknown
- Lead developer
- THOR Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
THOR-213 is an antisense oligonucleotide (ASO) therapeutic candidate developed by THOR Biopharma. It is designed to target the Macrophage Migration Inhibitory Factor (MIF) and its cognate receptor CD74, effectively inhibiting the MIF-CD74 signaling axis. This axis is known to play a critical role in promoting pro-inflammatory environments and tumor progression. By reducing the expression of these components through antisense-mediated knockdown, THOR-213 aims to treat diseases where MIF-CD74 signaling is dysregulated, such as autoimmune disorders and various cancers. The program is currently in the preclinical stage of development, specifically undergoing candidate optimization.
02
Targets
CD74 (Major histocompatibility complex class II invariant chain)Macrophage migration inhibitory factor mRNAMIF (Oxidized macrophage migration inhibitory factor)
Beyond the preview
Go deeper on THOR-213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THOR-213.